Firebrick Pharma Limited
AASX:FRE0.03
AUD
+0.00
(+7.14%)
Firebrick Pharma Limited
ASX:FRE
(Australian Securities Exchange)
Recent
price
0.03
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.- Similar Companies
- Business
- Firebrick Pharma Limited (ASX:FRE) develops and commercializes novel povidone-iodine (PVP-I) formulations for antiviral nasal applications targeting respiratory infections such as the common cold and COVID-19; its flagship product, Nasodine Nasal Spray (0.5% PVP-I), inactivates a broad spectrum of respiratory viruses and bacteria; the company advances additional Nasodine-branded products in development supported by extensive patents, peer-reviewed publications, and clinical data from Phase 1 through Phase 3 trials confirming safety and efficacy. Firebrick Pharma operates in the biotechnology and pharmaceutical manufacturing industry, serving consumer and healthcare markets in North America, Asia, Europe, and international regions with a focus on over-the-counter antiviral treatments. Founded in 2012 by Peter Molloy and Stephen Goodall and headquartered in Melbourne, Victoria, Australia, the company listed on the ASX in 2022. Recent developments include commercial-scale manufacturing completion and launches of Nasodine Nasal Spray in the USA in April 2024 and Singapore in June 2024, followed by a retail pharmacy rollout through Guardian Pharmacy Group in Singapore in 2025; Firebrick secured strategic investments from Philippines partner Pharma Nutria N.A., Inc. (PNAI), part of the SV More Group, totaling A$1.1 million in March 2025 and an additional $102,000 in October 2025 at a premium to restore PNAI's stake above 5%; the company achieved its first successful patent defense against a competitor nasal spray in 2025 and anticipates Nasodine approvals and launches in the Philippines and other markets in 2025-2026.